Updates
Updates
July 1, 2022
CureVac Netherlands BV
July 1 marks the official closing of the acquisition deal between CureVac NV and Frame Therapeutics BV. Frame will continue as a legal entity under the name CureVac Netherlands BV. This Dutch legal entity is a full subsidiary of the German holding CureVac AG. The Managing Board of CureVac Netherlands BV will consist of Prof. Ronald Plasterk and Dr. Wigard Kloosterman. The Supervisory Board will consist of Dr. Franz-Werner Haas (CEO), Pierre Kemula (CFO), and Dr. Marco Rau (General Counsel).
June 8, 2022
CureVac acquires Frame Cancer Therapeutics
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.
March 1, 2022
Frame attends live congresses in Spring 2022
CSO Wigard Kloosterman will be speaking on the identification of Frame neoantigens at the Neoantigen Summit Europe in Amsterdam and on Frame’s experiences applying long-read sequencing at The Jackson Laboratory for Genomic Medicine in Farmington, USA.
January 7, 2022
Clinical trial protocol approval
Frame's first clinical trial submission (short title ‘FRAME-001’) has officially been approved by the Dutch authorities at the CCMO (Central Committee on Research Involving Human Subjects). This trial will evaluate Frame’s personalized neoantigen based approach in ~15 patients with non-small-cell lung cancer.
November 10, 2021
Frame presents at scientific conferences
Recently Frame Therapeutics has participated in several conferences related to developing novel therapies. We have had the opportunity to share our unique approach and contribution to the growing field of cancer vaccines with big pharma, pioneering academics and leading biotech companies from the field.
April 22, 2021
Frame opens Immunology laboratory
With the opening of our second laboratory dedicated to Immunology Frame became one of the new tenants of the New West Health & Innovation District (Hid), initiated by and part of Sanquin.
March 8, 2021
Upcoming events
In the next weeks Frame will present at different virtual events about Whole Framome cancer vaccination. Our CEO Ronald Plasterk will attend Innovation for Health and CSO Wigard Kloosterman the Europe NEOANTIGEN Summit 2021.
December 15, 2020
December 15, 2020
eTheRNA immunotherapies & Frame Therapeutics collaboration is awarded with Eurostars research grant
eTheRNA immunotherapies & Frame Therapeutics collaboration is awarded with Eurostars research grant
A collaborative project between eTheRNA immunotherapies NV and Frame Therapeutics has been awarded a Eurostars grant totalling EUR 1.9 million for the development of a therapeutic vaccine for the treatment of kidney cancer. The Eurostars program aims to stimulate partnerships between European SMEs and start-ups to foster international collaboration and development of innovative technologies.
A collaborative project between eTheRNA immunotherapies NV and Frame Therapeutics has been awarded a Eurostars grant totalling EUR 1.9 million for the development of a therapeutic vaccine for the treatment of kidney cancer. The Eurostars program aims to stimulate partnerships between European SMEs and start-ups to foster international collaboration and development of innovative technologies.
May 6, 2020
May 6, 2020
Consortium Frame Therapeutics, Amsterdam UMC and UMC Groningen receives ERDF grant to develop cancer vaccines
Consortium Frame Therapeutics, Amsterdam UMC and UMC Groningen receives ERDF grant to develop cancer vaccines
A collaboration project between Frame Therapeutics and two clinical parties from the University Medical Centers in Amsterdam (Amsterdam UMC) and Groningen (UMCG) with a total research budget of 1.2 million Euros has received the Kansen voor West grant to cover 40% of the project named ‘Framome’. Kansen voor West is a subsidy that is part of the European Regional Development Fund (ERDF).
A collaboration project between Frame Therapeutics and two clinical parties from the University Medical Centers in Amsterdam (Amsterdam UMC) and Groningen (UMCG) with a total research budget of 1.2 million Euros has received the Kansen voor West grant to cover 40% of the project named ‘Framome’. Kansen voor West is a subsidy that is part of the European Regional Development Fund (ERDF).
April 22, 2020
April 22, 2020
Frame announces research collaboration with eTheRNA immunotherapies NV
Frame announces research collaboration with eTheRNA immunotherapies NV
Frame Therapeutics happily announces a new research collaboration with eTheRNA immunotherapies NV (eTheRNA) to develop mRNA cancer vaccines against immunogenic neoantigens.
Frame Therapeutics happily announces a new research collaboration with eTheRNA immunotherapies NV (eTheRNA) to develop mRNA cancer vaccines against immunogenic neoantigens.
Earlier updates
September 13th, 2019
September 13th, 2019
Frame successfully closes funding round
Frame successfully closes funding round
We are happy to report that Frame has found private investors, which will allow to bring the work into clinical testing.
We are happy to report that Frame has found private investors, which will allow to bring the work into clinical testing.
July 15th, 2019
July 15th, 2019
Frame Therapeutics receives prestigious SME instruments grant for starting companies
Frame Therapeutics receives prestigious SME instruments grant for starting companies
Based on a proposal ranked 'excellent', Frame Therapeutics B.V. obtained an SME instruments phase I grant to strengthen their business strategy towards market entry with personalized and off-the-shelf cancer vaccines for all cancer patients. Frame’s proposal scored in the top 5% out of almost 3,000 proposals submitted in this SME instruments funding round.
Based on a proposal ranked 'excellent', Frame Therapeutics B.V. obtained an SME instruments phase I grant to strengthen their business strategy towards market entry with personalized and off-the-shelf cancer vaccines for all cancer patients. Frame’s proposal scored in the top 5% out of almost 3,000 proposals submitted in this SME instruments funding round.
April 29th, 2019
April 29th, 2019
Paper on Frames in Nature Scientific Reports
Paper on Frames in Nature Scientific Reports
A Scientific Report by Koster and Plasterk, published on April 29th 2019, describes frame shifts in tumor driver genes. The frame shift mutations were found in public databases of over 10,000 different tumors from different cancer patients. These patients have nothing in common, except that they all have one or another form of cancer; that is the reason that they often have frame shift mutations in a small set of so-called ‘tumor driver’ genes.
A Scientific Report by Koster and Plasterk, published on April 29th 2019, describes frame shifts in tumor driver genes. The frame shift mutations were found in public databases of over 10,000 different tumors from different cancer patients. These patients have nothing in common, except that they all have one or another form of cancer; that is the reason that they often have frame shift mutations in a small set of so-called ‘tumor driver’ genes.
March 21, 2019
March 21, 2019
Opening Matrix VII
Opening Matrix VII
On the 21st of March, Matrix VII has been officially opened -with great festivities- by Amsterdam alderman of Economic Affairs Udo Kock. The building, designed by Ector Hoogstad architects, offers laboratory facilities for high-tech companies. Matrix VII is situated in Amsterdam Science Park. Today Amsterdam Science Park is the center par excellence when science and technology are involved.
On the 21st of March, Matrix VII has been officially opened -with great festivities- by Amsterdam alderman of Economic Affairs Udo Kock. The building, designed by Ector Hoogstad architects, offers laboratory facilities for high-tech companies. Matrix VII is situated in Amsterdam Science Park. Today Amsterdam Science Park is the center par excellence when science and technology are involved.
February 1, 2019
February 1, 2019
Start at Matrix VII building
Start at Matrix VII building
On the 1st of February Frame was launched in the brand-new Matrix VII building with a bang! The building of Matrix VII is built to become the epicentre of science and biotech.
On the 1st of February Frame was launched in the brand-new Matrix VII building with a bang! The building of Matrix VII is built to become the epicentre of science and biotech.
December 27, 2018
December 27, 2018
Frame founded
Frame founded
On the 27th of December 2018, Frame was officially founded by Ronald Plasterk, Dinko Valerio and Bob Lowenberg. The beginning of a new endeavour!
On the 27th of December 2018, Frame was officially founded by Ronald Plasterk, Dinko Valerio and Bob Lowenberg. The beginning of a new endeavour!
2018
2018
First patents filed
First patents filed
Ronald Plasterk, Founder and CEO of Frame filed the first of a series of patents early 2018. This was the first step to the start of Frame.
Ronald Plasterk, Founder and CEO of Frame filed the first of a series of patents early 2018. This was the first step to the start of Frame.
